Erythrocyte sedimentation rate--a predictor of malignant potential in early prostate cancer

Acta Oncol. 1997;36(7):689-94. doi: 10.3109/02841869709001338.

Abstract

The prognostic value of the erythrocyte sedimentation rate (ESR) was investigated in a population-based prostate cancer study, comparing 556 patients treated with no intent to cure. The data originated from hospital charts and death certificates. A statistically significant relationship between ESR at diagnosis and overall as well as disease-specific survival was demonstrated by univariate and multivariate analyses. A similar result was demonstrated in the 179 patients suffering from clinically organ-confined (T1-2,Nx,M0) disease. In a subpopulation consisting entirely of clinically organ-confined, small (T1), well-differentiated tumors, the dichotomized ESR (< or =20 mm/h vs. >20 mm/h) at the time of diagnosis distinguished between aggressive and non-aggressive tumors. In a small, second prostate cancer population it was demonstrated that ESR was not a surrogate marker for prostate- specific antigen (PSA). Our results indicate that ESR is a significant predictor of survival in early localized prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Sedimentation
  • Humans
  • Male
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / mortality
  • Survival Analysis

Substances

  • Prostate-Specific Antigen